Varenicline as compared to bupropion in smoking-cessation therapy-Cost-utility results for Sweden 2003

Respiratory Medicine

Volumn 102, Issue 5, 2008, Pages 699-710

  Bolin, Kristian ^a   Mörk, Ann Christin ^c   Willers, Stefan ^b   Lindgren, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

^b Unit of Preventive medicine   (Sweden)

^c PFIZER INC   (United States)

Author keywords

Bupropion; Economic evaluation; Smoking cessation intervention; Sweden; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SMOKING CESSATION; SWEDEN; TOBACCO DEPENDENCE;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; BUPROPION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MORBIDITY; QUALITY-ADJUSTED LIFE YEARS; QUINOXALINES; SMOKING CESSATION; SWEDEN; VALUE OF LIFE;

EID: 41149107938     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.12.018     Document Type: Article

References (45)

1. Doll R., and Hill A.B. The mortality of doctors in relation to their smoking habits. A preliminary report. BMJ 1 (1954) 1451-1455
2. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic cost-United States, 1995-1999. Morb Mortal Wkly Rep (MMWR) 2002;51:300-3.
3. Callum C. The UK smoking epidemic: deaths in 1995 (1998), UK Health Education Authority, London
4. Ruff L.K., Volmer T., Nowak D., et al. The economic impact of smoking in Germany. Eur Respir J 16 (2000) 385-390
5. Bolin K., and Lindgren B. Smoking, healthcare cost and lost productivity in Sweden, 2001. Scand J Public Health 35 (2007) 187-196
6. Klesges R.C., Johnson K.C., and Somes G. Varenicline for smoking cessation. JAMA 296 (2006) 94-95
7. Gonzales D., Rennard S.I., Nides M.A., et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
8. Jorenby D.E., Hays J.T., Rigotti N.A., et al. A randomized controlled trial comparing the efficacy of varenicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, to bupropion and to placebo for smoking cessation. JAMA 296 (2006) 56-63
9. Tonstad S., Tønnesen P., Hajek P., et al. Effect of maintenance therapy with varenicline for smoking cessation. JAMA 296 (2006) 64-71
10. Bolin K., Lindgren B., and Willers S. The cost utility of bupropion in smoking cessation health programs-simulation model results for Sweden. Chest 129 (2006) 651-660
11. Hoogendoorn M., Welsing P., and Rutten-van Mölken M. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 24 1 (2008) 51-61
12. Orme M.E., Hogue S.L., Kennedy L.M., et al. Development of the health and economic consequences of smoking interactive model. Tobacco Control 10 (2001) 55-61
13. Nishino Y., Inoue M., Tsuji I., et al. Tobacco smoking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 36 (2006) 800-807
14. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21 (2007) 27-42
15. Thun M.J., Apicella L.F., and Jane Henley S. Smoking versus other risk factors as the cause of smoking-attributable deaths. JAMA 284 6 (2000) 706-712
16. Edelstein-Keshet L. Mathematical models in biology. Birkhauser mathematics series (1998), Random House, New York
17. Kuntz K.M., and Weinstein M.C. Modelling in economic evaluation. In: Drummond M., and McGuire A. (Eds). Economic evaluation in health care-merging theory with practice (2001), Oxford University Press, Oxford 141-171
18. Swedish National Board of Health and Welfare. Mortality by causes. Various years.
19. Swedish National Board of Health and Welfare. Data on inpatient care. Various years.
20. Statistics Sweden. Life tables. Various years.
21. SOU (Statens offentliga utredningar) 2003:88.
22. Bolin K, Dozet A. Smoking-related diseases: individual costs over time. Lund University Centre for Health economics. Manuscript.
23. Läkemedelsstatistik A.B. Medical index Sweden (2002), Läkemedelsstatistik AB, Stockholm
24. Ghatnekar O., Persson U., Glader E.L., et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 20 (2004) 375-380
25. Fiscella K., and Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 275 (1996) 1247-1251
26. Spencer M., Briggs A., Grossman R., et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23 (2005) 619-637
27. Mannino D.M., Buist A.S., Petty T.L., et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 58 (2003) 388-393
28. Trippoli S., Vaiani M., Lucioni C., et al. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 19 (2001) 855-863
29. Hay J.W., and Sterling K.L. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 23 (2005) 133-141
30. American Heart Association. Heart disease and stroke statistics-2005 update. Dallas, Texas: American Heart Association; 2005 [©2005, American Heart Association].
31. Tengs T., and Lin T. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 21 (2003) 191-200
32. Duncan P.W., Lai S.M., and Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 39 (2000) 835-841
33. European Medicines Agency. Summary of product characterisation, 2006.
34. Willers S. Smoking cessation treatment-recommendations for Skåne, Sweden. Bakgrundsmaterial till Skånelistans rekommendationer 2007:168-73 [in Swedish]. 〈www.skane.se/lakemedelsradet〉.
35. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev (2007) CD000031
36. Statistics Sweden. Undersökningar av Levnadsförhållanden, 1996/1997.
37. Gonzales DH, Rennard SI, Billing CB, Reeves KR, Watsky E, Gong J. A pooled-analysis of varenicline, an alpha 4 beta 2 nicotinic receptor partial agonist vs. bupropion, an, for smoking cessation. SRNT 2007.
38. Wetter D., Cofta-Gunn L., Fouladi R., et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 39 6 (2004) 1156-1163
39. Krall E., Garvey A., and Garcia R. Smoking relapse after 2 years of abstinence: findings from the VA normative aging study. Nicotine Tob Res 4 (2002) 95-100
40. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16 (1997) 33-64
41. Ekman M. Studies in health economics-modelling and data analysis of costs and survival. Stockholm School of Economics, 2002 (Diss).
42. Hjelmgren J., Berggren F., and Andersson F. Health economic guidelines-similarities, differences, and some implications. Value Health 4 (2001) 225-250
43. Pharmaceutical Benefits Board of Sweden. General guidelines for economic evaluations. Stockholm, 2003. 〈www.lfn.se〉.
44. Lundin D., and Ramsberg J. On survival consumption costs-a reply to Nyman. Health Econ 17 (2008) 293-297
45. Nyman J.A. More on survival consumption costs in cost-utility analysis. Health Econ 15 (2006) 319-322